Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P62805 | 4/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19672499 | 0.94 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16707156 | 0.94 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16707174 | 0.90 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16707170 | 0.90 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16707178 | 0.89 | BRD4 (0.81) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16707151 | 0.88 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16707148 | 0.88 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL19672417 | 0.88 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16707163 | 0.88 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL15722556 | 0.86 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066104-B1 | TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-12-06 | — | — | EP | disclosed |
| US-9428513-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428513-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| WO-2015067770-A1 | TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133447-A1 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133447-A1 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133447-A1 | Triazolopyrazine | MKI67, TPX2, CCND3 | BRD4 1706/4885H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.